半个多世纪以来,恶性肿瘤药物治疗发展突飞猛进,不但涌现出大量新一代的细胞毒药物,随着人们对肿瘤进展与肿瘤细胞的某些分子生物学改变密切相关的发现,分子靶向药物应运而生。在恶性淋巴瘤临床治疗领域,靶向药物发挥着举足轻重的作用。 More than half a century, the development of malignant tumor drug treatment by leaps and bounds, not only the emergence of a large number of new generation of cytotoxic drugs, as people progress in cancer and tumor cells of certain molecular biology changes found that molecular targeted drugs should be transported And students. In the field of clinical treatment of malignant lymphoma, targeted drugs play a decisive role.